Eloxx Pharmaceuticals, Inc. (ELOX)

Eloxx Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	-	6.36	-	-	-
Gross Profit	-	6.36	-	-	-
Selling, General & Admin	3.38	5.25	8.69	10.69	20.45
Research & Development	3.06	3.58	8.6	23.73	22.9
Other Operating Expenses	-	-	-	-	22.67
Total Operating Expenses	6.44	8.83	17.29	34.42	66.02
Operating Income	-6.44	-2.47	-17.29	-34.42	-66.02
Total Non-Operating Income (Expense)	-0.44	0.68	-0.23	1.65	0.71
Pretax Income	-6.88	-1.79	-17.52	-32.77	-65.31
Net Income	-6	-3.14	-17.05	-36.07	-66.73
Net Income to Common	-6	-3.14	-17.05	-36.07	-66.73
Shares Outstanding (Basic)	1	0	0	0	0
Shares Outstanding (Diluted)	1	0	0	0	0
Shares Change (YoY)	228.50%	46.22%	18.66%	23.86%	74.36%
EPS (Basic)	-5.39	-9.24	-72.93	-183.15	-419.65
EPS (Diluted)	-5.39	-9.24	-72.93	-183.15	-419.65
EBIT	-6.44	-2.47	-17.29	-34.42	-66.02

Data Source: Fiscal.ai Last updated: May 5, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 25, 2026

Data Sources Report a data error